- Home
- MRNA vs FCNCA Comparison
MRNA vs FCNCA Comparison
Compare MRNA & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | FCNCA |
|---|---|---|
| Founded | 2010 | 1898 |
| Country | United States | United States |
| Employees | N/A | 18141 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 22.3B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | FCNCA |
|---|---|---|
| Price | $48.37 | $1,947.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $34.27 | ★ $2,199.64 |
| AVG Volume (30 Days) | ★ 7.0M | 57.0K |
| Earning Date | 05-01-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.43% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $9.36 | $3.43 |
| Revenue Next Year | $15.43 | N/A |
| P/E Ratio | ★ N/A | $12.17 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $1,625.08 |
| 52 Week High | $59.55 | $2,232.21 |
Technical Indicators
Market Signals| Indicator | MRNA | FCNCA |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 48.38 |
| Support Level | $46.30 | $1,911.07 |
| Resistance Level | $55.36 | $2,072.64 |
| Average True Range (ATR) | 3.63 | 45.72 |
| MACD | 0.03 | -6.50 |
| Stochastic Oscillator | 30.44 | 35.78 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About FCNCA First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $236 billion as of March 31, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.